Scribe Therapeutics priced an upsized $128.7 million IPO, strengthening funding for its liver-targeted gene silencing program STX-1150 and further early pipeline development. The company sold 8.58 million shares at $15.00 and also agreed to a concurrent private placement of 500,000 shares at the same price to Sanofi. Scribe’s lead program, STX-1150, is designed to epigenetically silence PCSK9 to lower LDL cholesterol, and it is in Phase I (NCT07428473). In its SEC filing, Scribe said it plans to allocate roughly $30 million to $35 million of IPO proceeds to support ongoing Phase I work, with additional funding earmarked for STX-1400 and preclinical STX-1200. Sanofi’s participation ties back to a prior research collaboration worth up to $1.5 billion, signaling continuity in partnership commitments as Scribe advances clinical testing.